Background: High-dose intravenous immunoglobulin (IVIg)has become a part of the treatment armentarium in pemphigus vulgaris (PV). Some consider IVIg as an adjuvant steroid sparing agent in PV, while others as disease ...Background: High-dose intravenous immunoglobulin (IVIg)has become a part of the treatment armentarium in pemphigus vulgaris (PV). Some consider IVIg as an adjuvant steroid sparing agent in PV, while others as disease modifying that can be used as monotherapy. Methods: We report our experience with a series of 12 PV patients with severe disease treated with IVIg as an adjuvant therapy. Results: Ten of 12 patients (83% ) showed response to six cycles of IVIg, six (50% ) having complete remission and four (33% ) having a partial response. This response rate is concordant with previous reports. The therapy was well tolerated. In all 12 patients, treatment with IVIg allowed a gradual reduction of prednisone dose compared with baseline levels. Conclusion: IVIg treatmentwas beneficial as asteroid sparing agent in our series of patients with severe PV.展开更多
Objective: This study was undertaken to study the tolerability and efficacy of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3. Study design: VIN grade 2/3 patients were ...Objective: This study was undertaken to study the tolerability and efficacy of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3. Study design: VIN grade 2/3 patients were recruited from regional colposcopy units. Imiquimod cream was applied over the abnormal area by the patient using an escalating dose regime for total treatment duration of 16 weeks. At the end of study, repeat colposcopy and biopsy of the target lesion were performed to assess for response. Results: Twenty- three patients participated. Twenty patients (87% ) had VIN grade 3. Nine patients (39% ) had multifocal disease on colposcopy. Therapy was well tolerated with the most commonly observed side effects being irritation at the application site. Responses were evaluable in 17 patients. Complete responses were observed in 9 patients with partial responses in another 5 (relative risk 82% ). The median time to response was 7 weeks. Conclusion: Imiquimod cream can induce histologic regression of high- grade VIN lesions and is well tolerated using a slow dose- escalating regime.展开更多
文摘Background: High-dose intravenous immunoglobulin (IVIg)has become a part of the treatment armentarium in pemphigus vulgaris (PV). Some consider IVIg as an adjuvant steroid sparing agent in PV, while others as disease modifying that can be used as monotherapy. Methods: We report our experience with a series of 12 PV patients with severe disease treated with IVIg as an adjuvant therapy. Results: Ten of 12 patients (83% ) showed response to six cycles of IVIg, six (50% ) having complete remission and four (33% ) having a partial response. This response rate is concordant with previous reports. The therapy was well tolerated. In all 12 patients, treatment with IVIg allowed a gradual reduction of prednisone dose compared with baseline levels. Conclusion: IVIg treatmentwas beneficial as asteroid sparing agent in our series of patients with severe PV.
文摘Objective: This study was undertaken to study the tolerability and efficacy of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3. Study design: VIN grade 2/3 patients were recruited from regional colposcopy units. Imiquimod cream was applied over the abnormal area by the patient using an escalating dose regime for total treatment duration of 16 weeks. At the end of study, repeat colposcopy and biopsy of the target lesion were performed to assess for response. Results: Twenty- three patients participated. Twenty patients (87% ) had VIN grade 3. Nine patients (39% ) had multifocal disease on colposcopy. Therapy was well tolerated with the most commonly observed side effects being irritation at the application site. Responses were evaluable in 17 patients. Complete responses were observed in 9 patients with partial responses in another 5 (relative risk 82% ). The median time to response was 7 weeks. Conclusion: Imiquimod cream can induce histologic regression of high- grade VIN lesions and is well tolerated using a slow dose- escalating regime.
